NCT06010290

The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients

The Novel 18F-labeled MAO-B PET/CT Imaging on Parkinsonism Patients of Chinese Population: a Prospective Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: Anhui Provincial Hospital · Other Government
• Sex: All
• Age: 40 Years – 90 Years
• Healthy volunteers: Accepted

Summary

This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.

Detailed description

18F-SMBT-1, the novel 18F-labeled MAO-B PET tracer, was evaluated reactive astrogliosis in Alzheimer's disease successfully. In this prospective study, we assess the changes of reactive astrocytes in cerebral gray matter and white matter on Parkinson's disease by 18F-SMBT-1 PET/CT imaging among Chinese population.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	18F-SMBT-1	Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.

Timeline

• Start date: 2022-11-30
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2023-08-24
• Last updated: 2023-08-24

Locations

1 site across 1 country: China